'Her legacy will live on': Phoenix Zoo announces death of 59-year-old Asian elephant Indu
The Phoenix Zoo said Indu had undergone treatment for osteoarthritis, a degenerative disease that weakens cartilage over time, and that she was struggling with age-related illnesses. The zoo said Indu's care team had been managing her conditions with daily medication, various treatments and therapies.
It had become difficult for Indu to manage her discomfort, and the Phoenix Zoo said they saw a decline in her mobility. Veterinarians and zookeeping staff recognized the decline in her health and decided to euthanize Indu on May 8.
Zoo representatives said she passed away surrounded by those who loved her the most — her dedicated care team.
"Indu was truly a remarkable elephant who touched the hearts of everyone who had the privilege to know her. Her gentle spirit, intelligence and resilience inspired not only our staff but also the millions of guests who visited her over the years," said President and CEO of the Phoenix Zoo Bert Castro. "Her legacy will live on through the stories we share, the connections she helped people form with wildlife and our continued commitment to the highest standards of animal care. She will be profoundly missed."
The Phoenix Zoo said Indu was considered elderly, surpassing the average life expectancy of 48 for elephants in facilities accredited by the Association of Zoos and Aquariums.
'The elephant Indu lived and thrived under the compassionate care of dedicated and expert professional staff at the Phoenix Zoo. Her 59 years of life is a testament to the focus on animal care and wellbeing that is a hallmark of the Phoenix Zoo and all AZA-accredited members,' said Dan Ashe, president and CEO of the association.
Indu arrived at the Phoenix Zoo in 1998 and quickly became an ambassador for Asian elephants, a species classified as endangered.
'Indu has captivated the hearts of guests and staff alike with her gentle nature and immense presence,' said Heather Wright, elephant collection manager at the zoo. 'Indu has made and continues to leave an indelible impression on all who have the privilege to care for her and the guests who have had the joy of seeing her. We thank you for your support and condolences during this difficult time.'
The Phoenix Zoo said Indu's story brought awareness to the challenges faced by elephants in the wild and inspired countless guests to advocate for conservation efforts.
"Her imposing stature was matched only by her gentle demeanor, and she brought smiles to the faces of countless guests, from wide-eyed children seeing an elephant for the first time to lifelong Zoo supporters who came back time and again to visit her," the statement from the Phoenix Zoo said.
The zoo said they take solace in the profound impact she had on everyone who had the privilege of knowing her.
The Phoenix Zoo honored Indu's memory with a webpage featuring photos, videos and memories shared by staff and zookeepers who deeply loved Indu.
This article originally appeared on Arizona Republic: Phoenix Zoo reveals the death of beloved 59-year-old elephant Indu
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
High Growth Tech Stocks in Asia Featuring Takara Bio and Two Others
As Asian markets continue to navigate a complex landscape of economic indicators and trade negotiations, the tech sector stands out with its potential for high growth, driven by innovation and evolving consumer demands. In this environment, identifying promising stocks involves looking for companies that demonstrate resilience and adaptability in the face of changing market conditions, such as those featured in our discussion on Takara Bio and two other noteworthy tech firms. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.79% 22.79% ★★★★★★ Ugreen Group 20.48% 26.05% ★★★★★★ Shanghai Huace Navigation Technology 25.38% 24.34% ★★★★★★ PharmaEssentia 31.53% 65.34% ★★★★★★ Fositek 31.22% 40.16% ★★★★★★ Eoptolink Technology 33.64% 33.77% ★★★★★★ Shengyi Electronics 26.23% 37.08% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 24.93% 24.09% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Takara Bio Simply Wall St Growth Rating: ★★★★☆☆ Overview: Takara Bio Inc. operates in the fields of reagents, equipment, contract services, and genetic medicine across various regions including Japan, China, Asia, the United States, and Europe with a market capitalization of ¥107.53 billion. Operations: Takara Bio generates revenue through its diverse operations in reagents, equipment, contract services, and genetic medicine across multiple regions. The company focuses on leveraging its expertise in biotechnology to provide innovative solutions for research and healthcare applications. Takara Bio, a contender in Asia's high-growth tech sector, showcases a robust earnings trajectory with an annual growth rate of 29.66%, significantly outpacing the broader Japanese market's 8%. Despite a substantial one-off loss of ¥531M impacting its recent financials, the company has demonstrated exceptional profit growth over the past year at 406.1%, dwarfing the biotech industry's average of 11.6%. However, challenges persist as its revenue growth projection stands at just 4.9% per year, slightly above Japan's market average but below high-growth benchmarks. The firm's R&D commitment is crucial for sustaining innovation and competitiveness in this rapidly evolving sector. Dive into the specifics of Takara Bio here with our thorough health report. Learn about Takara Bio's historical performance. Good Will Instrument Simply Wall St Growth Rating: ★★★★★☆ Overview: Good Will Instrument Co., Ltd. specializes in the production and distribution of electrical test and measurement instruments for educational and industrial manufacturing sectors, with a market cap of NT$7.57 billion. Operations: Good Will Instrument generates revenue primarily from the sale of electronic test and measurement instruments, totaling NT$2.85 billion. The company serves both educational and industrial manufacturing markets. Good Will Instrument, amid Asia's competitive tech landscape, is demonstrating robust growth with reported annual revenue and earnings increases of 50.8% and 49.5%, respectively. This performance significantly surpasses the TW market averages of 10.1% for revenue and 15.3% for earnings growth, highlighting its potential in a rapidly evolving sector. The company's commitment to innovation is evident from its R&D investments, crucial for maintaining its competitive edge in technology development. Recent financials reveal a strong upward trajectory with first-half sales reaching TWD 1.37 billion, up from TWD 1.32 billion year-over-year, complemented by a net income rise to TWD 174.4 million from TWD 146.28 million in the previous period. Click here to discover the nuances of Good Will Instrument with our detailed analytical health report. Review our historical performance report to gain insights into Good Will Instrument's's past performance. Sercomm Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sercomm Corporation is engaged in the research, development, manufacturing, and sale of networking communication software and equipment across North America, Europe, and the Asia Pacific with a market capitalization of NT$31.02 billion. Operations: The company's primary revenue stream comes from its computer networks segment, generating NT$50.45 billion. Sercomm's recent financial performance indicates a challenging phase, with second-quarter sales dropping to TWD 12.2 billion from TWD 13.7 billion year-over-year and net income falling significantly to TWD 334.32 million from TWD 545.21 million. Despite these setbacks, the company is actively enhancing its strategic partnerships, notably with Vecima Networks, to strengthen its position in the PON technology sector for broadband services—a move that could stabilize and potentially increase future revenue streams. Additionally, Sercomm has demonstrated a commitment to shareholder returns by repurchasing over 3 million shares for TWD 302.29 million earlier this year, reflecting confidence in its operational adjustments and market strategy moving forward. Get an in-depth perspective on Sercomm's performance by reading our health report here. Assess Sercomm's past performance with our detailed historical performance reports. Key Takeaways Click here to access our complete index of 180 Asian High Growth Tech and AI Stocks. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TSE:4974 TWSE:2423 and TWSE:5388. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
3 days ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
Yahoo
3 days ago
- Yahoo
Exploring High Growth Tech Stocks In Asia
As global markets react to economic data and rate cut speculations, the Asian tech sector is drawing attention with its potential for high growth amidst easing U.S.-China trade tensions. In this dynamic environment, identifying stocks with strong innovation capabilities and resilience to market fluctuations can be key for investors looking to capitalize on the region's technological advancements. Top 10 High Growth Tech Companies In Asia Name Revenue Growth Earnings Growth Growth Rating Accton Technology 22.79% 22.79% ★★★★★★ Shanghai Huace Navigation Technology 25.38% 24.34% ★★★★★★ PharmaEssentia 31.53% 65.34% ★★★★★★ Fositek 31.22% 40.16% ★★★★★★ Eoptolink Technology 33.64% 33.77% ★★★★★★ Shengyi Electronics 26.23% 37.08% ★★★★★★ Zhejiang Meorient Commerce Exhibition 26.71% 35.89% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 24.93% 24.09% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★ Click here to see the full list of 180 stocks from our Asian High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Shanghai OPM Biosciences Simply Wall St Growth Rating: ★★★★★☆ Overview: Shanghai OPM Biosciences Co., Ltd. operates by offering cell culture media and CDMO services both in China and internationally, with a market capitalization of CN¥6.39 billion. Operations: The company generates revenue through the provision of cell culture media and CDMO services across domestic and international markets. It holds a market capitalization of approximately CN¥6.39 billion. Shanghai OPM Biosciences, amidst a challenging year with earnings contraction by 67.3%, still projects robust future growth, with anticipated revenue and earnings increases of 23.8% and 53.6% annually, outpacing the Chinese market norms of 12.9% and 23.9%, respectively. Despite a significant drop in profit margins from 19.4% to 5.4%, the firm maintains positive free cash flow and is set for a pivotal shareholders meeting that could steer its strategic direction amidst these volatile conditions. This biotech entity's commitment to innovation is evident from its R&D focus, although specific financials on this expenditure aren't disclosed here; such investment is critical in sustaining long-term competitiveness in the fast-evolving sector where technological advancements rapidly redefine market dynamics. Click to explore a detailed breakdown of our findings in Shanghai OPM Biosciences' health report. Review our historical performance report to gain insights into Shanghai OPM Biosciences''s past performance. Taiwan Union Technology Simply Wall St Growth Rating: ★★★★★☆ Overview: Taiwan Union Technology Corporation manufactures and sells copper foil substrates, adhesive sheets, and multi-layer laminated boards both in Taiwan and internationally, with a market capitalization of NT$87.56 billion. Operations: The company focuses on producing copper foil substrates, adhesive sheets, and multi-layer laminated boards for both domestic and international markets. Its revenue model is centered around these core products, contributing significantly to its financial performance. Taiwan Union Technology has demonstrated robust financial performance, with a significant 19.2% annual revenue growth and an impressive 31.8% increase in earnings per year, outstripping the Taiwanese market norms of 10.1% and 15.3%, respectively. The company's commitment to innovation is underscored by its R&D investments, crucial for maintaining competitiveness in the rapidly evolving tech landscape. Recent dividends and amendments to company bylaws reflect proactive governance, aligning with strategic goals that could shape its trajectory in Asia's high-tech sector. Take a closer look at Taiwan Union Technology's potential here in our health report. Gain insights into Taiwan Union Technology's past trends and performance with our Past report. CELSYS Simply Wall St Growth Rating: ★★★★☆☆ Overview: CELSYS, Inc. operates in the content creation solutions sector in Japan and has a market capitalization of ¥53.32 billion. Operations: The company focuses on providing content creation solutions in Japan. It operates through various revenue streams, primarily driven by software sales and related services. CELYS is actively enhancing its financial agility and market presence, as evidenced by its recent share repurchase program aimed at improving capital efficiency. The initiative to buy back 500,000 shares for ¥500 million underscores a strategic approach to capital management amidst evolving business conditions. Additionally, the establishment of CELSYS UK Ltd. marks a significant step in expanding global payment solutions, aligning with the company's growth trajectory in software offerings like CLIP STUDIO PAINT. This expansion not only diversifies their service platform but also promises to bolster corporate value over time. With an impressive forecast of 24.2% annual earnings growth and a revenue increase expectation of 10.3% per year outpacing Japan's market average, CELSYS is poised to strengthen its position in the competitive tech landscape through these calculated operational enhancements and financial strategies. Dive into the specifics of CELSYS here with our thorough health report. Understand CELSYS' track record by examining our Past report. Turning Ideas Into Actions Click this link to deep-dive into the 180 companies within our Asian High Growth Tech and AI Stocks screener. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:688293 TPEX:6274 and TSE:3663. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
